Novo Nordisk A/S (NYSE:NVO) Receives $65.56 Consensus PT from Analysts

Novo Nordisk A/S (NYSE:NVO) has been given a consensus rating of “Hold” by the twenty-three research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, seventeen have issued a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $65.5625.

NVO has been the subject of a number of recent research reports. Wolfe Research initiated coverage on Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Weiss Ratings lowered Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Finally, Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 target price for the company.

Novo Nordisk A/S Trading Up 3.3%

Shares of NVO stock opened at $47.38 on Wednesday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $43.29 and a two-hundred day moving average price of $45.82. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $71.79. The firm has a market cap of $211.55 billion, a P/E ratio of 11.12, a price-to-earnings-growth ratio of 4.10 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. Equities analysts anticipate that Novo Nordisk A/S will post 3.45 EPS for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quotient Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 2.0% in the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after purchasing an additional 177 shares during the last quarter. Certuity LLC increased its holdings in shares of Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock valued at $257,000 after purchasing an additional 177 shares during the last quarter. Oakworth Capital Inc. increased its holdings in shares of Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after purchasing an additional 182 shares during the last quarter. True North Advisors LLC boosted its position in shares of Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after acquiring an additional 199 shares during the period. Finally, Revolve Wealth Partners LLC boosted its position in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after acquiring an additional 200 shares during the period. Institutional investors own 11.54% of the company’s stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk Foundation, the company’s primary owner, launched a EUR 60.2 million pan-European research initiative to speed development of obesity and diabetes treatments, reinforcing the long-term pipeline and innovation outlook. Novo Nordisk A/S (NVO) Primary Owner to Open Obesity Drug Incubators Across Europe
• Positive Sentiment: Market coverage highlighted NVO strength after the foundation-backed cardiometabolic research push, suggesting renewed investor optimism around Novo Nordisk’s obesity and diabetes growth story. NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
• Positive Sentiment: Recent articles also pointed to momentum after UK approval for oral Wegovy, which may expand Novo Nordisk’s addressable market and improve the product’s commercial potential. Novo Nordisk (NVO) Stock Surges 6.55% on Oral Wegovy UK Approval

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.